{"id":5378,"date":"2025-12-17T22:22:32","date_gmt":"2025-12-17T19:22:32","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5378"},"modified":"2025-12-17T22:33:23","modified_gmt":"2025-12-17T19:33:23","slug":"satellos-sat-3247-phase-2-basecamp-clinical-trial-nct07287189","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/satellos-sat-3247-phase-2-basecamp-clinical-trial-nct07287189\/","title":{"rendered":"Satellos annonce le lancement de l&#039;\u00e9tude de phase 2A (BASECAMP) du SAT-3247 chez des patients ambulatoires atteints de dystrophie musculaire de Duchenne."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Satellos a annonc\u00e9 le lancement d&#039;un essai de phase 2A du SAT-3247 (NCT07287189) chez des patients ambulatoires atteints de dystrophie musculaire de Duchenne, \u00e2g\u00e9s de 7 \u00e0 10 ans. Cet essai \u00e9valuera deux doses de SAT-3247 sur une p\u00e9riode de 12 semaines, selon un protocole randomis\u00e9, en double aveugle, contr\u00f4l\u00e9 par placebo et administr\u00e9 chaque semaine, afin de d\u00e9terminer la dose optimale, la s\u00e9curit\u00e9, la tol\u00e9rance et l&#039;efficacit\u00e9 pr\u00e9liminaire. <strong>Apprendre encore plus<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/fr\/satellos-receives-fda-and-international-clearance-to-commence-pediatric-phase-2-testing-of-sat-3247-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Le Satellos re\u00e7oit l&#039;autorisation du FDA et l&#039;autorisation internationale pour entamer les essais p\u00e9diatriques de phase 2 du SAT-3247 dans le traitement de la dystrophie musculaire de Duchenne.<\/a><\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table des mati\u00e8res<\/h2><nav><ul><li><a href=\"#what-is-sat-3247-phase-2-a-clinical-trial\">Qu\u2019est-ce que l\u2019essai clinique de phase 2A SAT-3247\u00a0?<\/a><\/li><li><a href=\"#rag-18-sa-rna-early-phase-1-nct-07282652\">SAT-3247 Phase 2A \u2013 NCT07287189<\/a><\/li><li><a href=\"#how-to-participate-in-the-wve-n-531-clinical-trial\">Comment participer \u00e0 l&#039;essai clinique de phase 2A du SAT-3247<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-sat-3247-phase-2-a-clinical-trial\">Qu\u2019est-ce que l\u2019essai clinique de phase 2A SAT-3247\u00a0?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Il s&#039;agit d&#039;un essai mondial de phase 2a \u00e9valuant le SAT-3247 chez des patients ambulatoires atteints de dystrophie musculaire de Duchenne (DMD) \u00e2g\u00e9s de 7 \u00e0 moins de 10 ans. L&#039;essai \u00e9tudiera deux doses de SAT-3247 selon un sch\u00e9ma d&#039;administration randomis\u00e9, en double aveugle et contr\u00f4l\u00e9 par placebo, administr\u00e9es en semaine pendant 12 semaines, afin de d\u00e9terminer la dose optimale, la s\u00e9curit\u00e9, la tol\u00e9rance et l&#039;efficacit\u00e9 pr\u00e9liminaire. Une dose de SAT-3247 et un placebo seront \u00e9tudi\u00e9s aux \u00c9tats-Unis et au Canada\u00a0; deux doses de SAT-3247 et un placebo seront \u00e9tudi\u00e9s au Royaume-Uni, dans l&#039;Union europ\u00e9enne, en Serbie et en Australie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Il est pr\u00e9vu d&#039;inclure jusqu&#039;\u00e0 51 patients ambulatoires atteints de dystrophie musculaire de Duchenne (DMD) \u00e2g\u00e9s de 7 \u00e0 moins de 10 ans, \u00e0 l&#039;\u00e9chelle mondiale. La randomisation sera stratifi\u00e9e en fonction du traitement initial par corticost\u00e9ro\u00efdes et des traitements concomitants ant\u00e9rieurs de la DMD.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chaque participant recevra une dose quotidienne de SAT-3247 ou un placebo correspondant pendant 12 semaines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les participants seront \u00e9valu\u00e9s dans les 28 jours pr\u00e9c\u00e9dant le d\u00e9but de l&#039;administration du produit exp\u00e9rimental (visite initiale). Apr\u00e8s cette p\u00e9riode d&#039;\u00e9valuation, ils effectueront une visite initiale (visite 2), un appel de suivi \u00e0 la semaine 1, puis des visites aux semaines 4 (visite 3), 8 (visite 4) et 12 (visite 5).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"rag-18-sa-rna-early-phase-1-nct-07282652\">SAT-3247 Phase 2A \u2013 NCT07287189<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Une \u00e9tude de phase 2a, randomis\u00e9e, en double aveugle, contr\u00f4l\u00e9e par placebo, comparant les doses et \u00e9valuant l&#039;efficacit\u00e9 exploratoire du SAT-3247 administr\u00e9 par voie orale chez des patients atteints de DMD ambulatoires.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><strong>D\u00e9but des \u00e9tudes (r\u00e9el)<\/strong><\/strong>: 2025-12-08<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement du primaire (estim\u00e9)<\/strong>: 2026-03-31<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2026-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre de participants (estim\u00e9)<\/strong>: 51<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Type d&#039;\u00e9tude<\/strong>: Interventionnel<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Emplacement<\/strong>\u00c9tats-Unis, Australie, Canada, Serbie, Royaume-Uni<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c2ges admissibles aux \u00e9tudes<\/strong>: 7 \u00e0 9 ans (gar\u00e7on)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Principaux crit\u00e8res d\u2019inclusion et d\u2019exclusion. \u2013\u00a0<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07287189\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07287189<\/a>\u00a0\u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-to-participate-in-the-wve-n-531-clinical-trial\">Comment participer \u00e0 l&#039;essai clinique de phase 2A du SAT-3247<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pour participer \u00e0 l&#039;essai clinique de phase 2A SAT-3247, vous pouvez utiliser les informations de contact ci-dessous.\u00a0<strong>Apprendre encore plus<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/fr\/how-to-participate-in-clinical-trials-for-duchenne\/\" target=\"_blank\" rel=\"noreferrer noopener\">Comment participer aux essais cliniques pour la maladie de Duchenne (DMD) ?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les coordonn\u00e9es des personnes pouvant r\u00e9pondre aux questions concernant la participation \u00e0 l&#039;\u00e9tude, ainsi que des informations sur le lieu o\u00f9 l&#039;\u00e9tude est men\u00e9e, seront publi\u00e9es.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Essais cliniques sur la dystrophie musculaire de Duchenne (Liste de toutes les recherches)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Satellos announced the commencement of a Phase 2A trial of SAT-3247 (NCT07287189) in ambulatory patients with Duchenne aged 7 to 10 years. In this trial, two doses of SAT-3247 will be studied over 12 weeks in a randomized, double-blind, placebo-controlled, intraweek regimen to determine the optimal dose, safety, tolerance, and preliminary efficacy. Learn More: Satellos [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5381,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[171,303,137,242,470,251,252,253],"class_list":["post-5378","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-canada","tag-cell-therapy","tag-clinical-trial","tag-clinical-trials","tag-nct07287189","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=5378"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5378\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/5381"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=5378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=5378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=5378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}